First Biotech to complete a Phase III for Long Hauler COVID-19 symptoms
By Robert Millar | February 9, 2022 | Blog
EmphyCorp www.EmphyCorp.com is the first Biotech to complete a Phase III for COVID Long Hauler symptoms.
Our Patented Rx N115 Nasal Spray technology immediately clears the nose of congestion and increases Nasal Nitric Oxide to kill all viruses, bacteria, and fungi. It also improves breathing, increases Sa02 and lung functions. N115 reduces hypoxemia (low SaO2), fatigue, coughing/sneezing, trouble breathing, body aches, headaches in patients with Long Hauler COVID symptoms and improved all lung functions in patients with Pulmonary Fibrosis.
Dr. Martin, “Being a Non-Steroidal spray that increases nasal nitric oxide is key, because nasal steroids and other OTC nasal treatments shut down the synthesis of nasal nitric oxide, which then leads to decreased lung function and a 12%-34% increase in infections, depending upon age or underlying disease.”
“Given our success in treating Pulmonary Fibrosis patients and the other respiratory diseases, our research focused on treating the symptoms in COVID-19 infected patients and in long hauler COVID patients, including hypoxemia (low SaO2), fatigue, coughing/sneezing, trouble breathing, body aches, headaches, and preventing lung fibrosis”.
There are approximately twelve million Americans with COVID-19 Long Hauler Symptoms, including athletes, which are at serious risk of developing Pulmonary Fibrosis (7-10% JAMA). Conversely, patients with Pulmonary Fibrosis have an increased risk and susceptibility to COVID-19 infection, which can reach a mortality rate of 50%. N115 is poised to help COVID-19 Long Haulers recover from this disease by reducing their symptoms including hypoxemia low (SaO2), fatigue, coughing/sneezing, trouble breathing, body aches, headaches, and lung damage.
EmphyCorp Patented Rx N115 Nasal Spray with no know side effects has successfully completed Phase III Clinical Trials for Pulmonary Fibrosis, COVID-19, and COVID Long Haulers.
To download the Press Release with Phase III Results, please go to the EmphyCorp Website PR-Newswire-EmphyCorp-Inc.-N115-Nasal-Spray-Completed-Phase-III-Clinical-Trial-for-COVID-19-Long-Haulers-and-Pulmonary-Fibrosis-100521.pdf (netdna-ssl.com)